Super NK cell therapy (Hangzhou Qihan)

N/A

Report date: 2026/02/12 20:00:14

Base Information

Drug NameSuper NK cell therapy (Hangzhou Qihan)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsNeoplasm, ResidualLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Qihan Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Qihan Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasm, ResidualLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A